M/P 65℃ PI4.8 Albumin Skin Care Freeze Dried Powder For Anti - Wrinkling Cosmetics

M/P 65℃ Albumin Skin Care Freeze Dried Powder For Anti - Wrinkling Cosmetics

Quick detail

1. Amino Acids Sequence: Same as the HSA from plasma
2. N-terminus: DAHKSEV
3. C-terminus: KLVAASQAALGL
4. Glycosylation: No
5. PI:4.8
6. Thermal Stability: M/P 65℃
7. Lipid Conjugation: Same as the HSA from plasma
8. Crystal Structure: Same as the HSA from plasma

Description

OsrHSA is a kind of neutral buffer and has good biocompatibility as a water-soluble protein. The OsrHSA can shape a moisture film on skin surface, accelerate the rate of collagen synthesis in the process of skin damage, increase the sensitivity of vascular endothelial cell receptor, and accelerate the recovery of damaged epithelial tissue cells. These features effectively help to remove wrinkles, age signs and and keep skin comfortable, smooth and moisturizing.

Advantages

1. Healthgen Biotech recombinant human serum albumin is free of animal origin, which effectively avoid any potential risk of animal bacteria, prions, virus and contagious protein disease.

2. Healthgen Biotech recombinant human serum albumin (OsrHSA) has excellent batch consistency. Using self-pollination rice as the bioreactor to express the OsrHSA, with the world's advanced facility and top production proceeding to extract and purify the OsrHSA, Healthgen Biotech can ensure the excellent consistency of OsrHSA from different batches.

3. The rice endosperm specific expression platform is easy to be large-scale. The rice endosperm has the protein body, which can keeps proteins stability and bioactivity. At present, the production capacity is almost 1000 kg / year.

Supplemental Description

Healthgen Biotech, always pay great attention to the original technological innovation and intellectual property protection, has the titles of “Hubei Province Molecular Pharmaceutical Engineering Research Center” and “Protein Purification Research Center”. The rice endosperm cell high expression technology platform and other core technology have applied and gained 13 domestic and international patents; and won the “2012 Hubei Provincial Science and technology invention Award”, “2013 National Science and Technology Invention Award and China Patent Excellence Award’. The project obtained the funding from the National Ministry of science and high technology “863 plan”, Major national science and technology plan “Major projects of new varieties of genetically modified organisms” and “Major projects for new drug discovery”, the National Development and Reform Commission “Pilot development of strategic emerging industries”, National Ministry of science and technology innovation fund and state and local plans for all kinds of talented people funding. In July 2015, Healthgen Biotech became a public company on the "China New OTCBB", a national share transfer system for SMEs and officially known as the National Equities Exchange and Quotations, which is the “first stock” of the plant-derived pharmaceutical in China and even the world.